Sanofi, Regeneron’s Libtayo scores UK watchdog’s approval in common form of skin cancer kdunleavy Thu, 05/26/2022 – 11:02 More: Sanofi, Regeneron's Libtayo scores UK watchdog's approval in common form of skin cancer Source: fierce
read moreASCO: Merck touts Keytruda’s ‘convergent’ benefits across postsurgery lung cancer patient groups aliu Thu, 05/26/2022 – 10:34 More: ASCO: Merck touts Keytruda's 'convergent' benefits across postsurgery lung cancer patient groups Source: fierce
read moreServier’s Tibsovo snags FDA combo nod in first-line AML, expanding its use in tough-to-treat cancer esagonowsky Thu, 05/26/2022 – 10:03 More: Servier's Tibsovo snags FDA combo nod in first-line AML, expanding its use in tough-to-treat cancer Source: fierce
read moreLibtayo has been approved for adults when curative surgery or radiation is not appropriate More: NICE recommendation for Sanofi and Regeneron’s CSCC treatment Source: News
read moreApproval provides another step forward in transforming multiple myeloma outcomes and eliminating the disease More: EC approves Janssen T-cell therapy for multiple myeloma treatment Source: News
read moreEli Lilly plots $2.1B manufacturing expansion at America’s crossroads, with 500 new hires fkansteiner Wed, 05/25/2022 – 13:48 More: Eli Lilly plots .1B manufacturing expansion at America's crossroads, with 500 new hires Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals